written on 26.02.2014
Tags:
,

InterMune ASCENDs on new Phase III pirfenidone data

TAGS: ,

Brisbane, California-based InterMune's stock soared 170.8% higher on 25 February to close at $37.80 per share with a $3bn market cap after the company said pirfenidone cut the percentage of IPF patients who died or experienced a 10% decrease in lung…

Latest Report